Annual CFO
-$12.25 M
+$3.71 M+23.24%
December 31, 2024
Summary
- As of February 27, 2025, NVCT annual cash flow from operations is -$12.25 million, with the most recent change of +$3.71 million (+23.24%) on December 31, 2024.
- During the last 3 years, NVCT annual CFO has fallen by -$2.74 million (-28.86%).
- NVCT annual CFO is now -28.86% below its all-time high of -$9.50 million, reached on December 31, 2021.
Performance
NVCT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
N/A
December 31, 2024
Summary
- NVCT quarterly cash flow from operations is not available.
Performance
NVCT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFO
N/A
December 31, 2024
Summary
- NVCT TTM cash flow from operations is not available.
Performance
NVCT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
NVCT Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +23.2% | - | - |
| 3 y3 years | -28.9% | - | - |
| 5 y5 years | - | - | - |
NVCT Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -28.9% | +23.2% | ||||
| 5 y | 5-year | -28.9% | +23.2% | ||||
| alltime | all time | -28.9% | +23.2% |
Nuvectis Pharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$12.25 M(-23.2%) | - | - |
| Sep 2024 | - | -$2.40 M(-20.4%) | -$13.63 M(-5.8%) |
| Jun 2024 | - | -$3.02 M(-30.7%) | -$14.47 M(-6.8%) |
| Mar 2024 | - | -$4.36 M(+13.2%) | -$15.54 M(-2.6%) |
| Dec 2023 | -$15.95 M(+17.7%) | -$3.85 M(+18.7%) | -$15.95 M(+2.1%) |
| Sep 2023 | - | -$3.24 M(-20.5%) | -$15.62 M(-7.0%) |
| Jun 2023 | - | -$4.08 M(-14.5%) | -$16.80 M(+10.1%) |
| Mar 2023 | - | -$4.78 M(+35.9%) | -$15.26 M(+12.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | -$13.56 M(+42.7%) | -$3.52 M(-20.5%) | -$13.56 M(+22.0%) |
| Sep 2022 | - | -$4.42 M(+74.0%) | -$11.11 M(-0.0%) |
| Jun 2022 | - | -$2.54 M(-17.3%) | -$11.11 M(-11.7%) |
| Mar 2022 | - | -$3.08 M(+188.3%) | -$12.58 M(+32.4%) |
| Dec 2021 | -$9.50 M | -$1.07 M(-75.9%) | -$9.50 M(+12.6%) |
| Sep 2021 | - | -$4.43 M(+10.3%) | -$8.44 M(+110.3%) |
| Jun 2021 | - | -$4.01 M(<-9900.0%) | -$4.01 M(<-9900.0%) |
| Mar 2021 | - | $0.00 | $0.00 |
FAQ
- What is Nuvectis Pharma annual cash flow from operations?
- What is the all time high annual CFO for Nuvectis Pharma?
- What is Nuvectis Pharma annual CFO year-on-year change?
- What is the all time high quarterly CFO for Nuvectis Pharma?
- What is the all time high TTM CFO for Nuvectis Pharma?
What is Nuvectis Pharma annual cash flow from operations?
The current annual CFO of NVCT is -$12.25 M
What is the all time high annual CFO for Nuvectis Pharma?
Nuvectis Pharma all-time high annual cash flow from operations is -$9.50 M
What is Nuvectis Pharma annual CFO year-on-year change?
Over the past year, NVCT annual cash flow from operations has changed by +$3.71 M (+23.24%)
What is the all time high quarterly CFO for Nuvectis Pharma?
Nuvectis Pharma all-time high quarterly cash flow from operations is $0.00
What is the all time high TTM CFO for Nuvectis Pharma?
Nuvectis Pharma all-time high TTM cash flow from operations is $0.00